SCHEMBL1534480

SCHEMBL1534480

CC(C)(C)OC(=O)NC1(c2ccc(-c3c(-c4ccccc4)oc4cccc(F)c4c3=O)cc2)CCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 2/20 0.41
AKT2 P31751 1/20 0.41
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
HSP90AA1 P07900 1/20 0.36
PDE2A O00408 5/20 0.35
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34
KIT P10721 1/20 0.34
MAPK14 Q16539 1/20 0.33
CYP3A4 P08684 2/20 0.33
CYP2C8 P10632 1/20 0.33
PLA2G2A P14555 1/20 0.33
PLA2G4A P47712 1/20 0.33
SRC P12931 2/20 0.33
SCN9A Q15858 1/20 0.33
LMNA P02545 2/20 0.32
MAPT P10636 2/20 0.32
AR P10275 1/20 0.32
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1534619 0.87 PLA2G2A (0.46) AKT1AKT2MEN1KMT2AMAPK14
SCHEMBL1901791 0.87 PLA2G2A (0.46) AKT1AKT2MEN1KMT2AMAPK14
SCHEMBL1534621 0.87 AKT1 (0.42) AKT1AKT2MEN1KMT2AHSP90AA1
SCHEMBL1534526 0.87 AKT1 (0.40) AKT1AKT2MEN1KMT2APDE2A
SCHEMBL1534850 0.85 AKT1 (0.42) AKT1AKT2PDE2ACNR1CNR2
SCHEMBL1534320 0.85 CYP3A4 (0.42) AKT1AKT2MEN1KMT2APDE2A
SCHEMBL1907185 0.81 AKT1 (0.41) AKT1AKT2PDE2ACNR1CNR2
SCHEMBL1534821 0.81 AKT1 (0.44) AKT1AKT2MEN1KMT2APDE2A
SCHEMBL1534534 0.81 AKT1 (0.45) AKT1AKT2MEN1KMT2APDE2A
SCHEMBL1534525 0.81 AKT1 (0.43) AKT1AKT2MEN1KMT2ACNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546376-B2 Pharmaceutical compounds ALMAC DISCOVERY LIMITED (GB) 2013-10-01 US disclosed
US-20120238541-A1 PHARMACEUTICAL COMPOUNDS ALMAC DISCOVERY LIMITED (GB) 2012-09-20 US disclosed
EP-2473495-A1 PHARMACEUTICAL COMPOUNDS Almac Discovery Limited (GB) 2012-07-11 EP disclosed
WO-2011033265-A1 PHARMACEUTICAL COMPOUNDS ALMAC DISCOVERY LIMITED (GB) 2011-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238541-A1 PHARMACEUTICAL COMPOUNDS PIK3CA, PLK1, MTOR AKT1 6/4885AKT2 4/4885MEN1 645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.